Correlation between the positive expression of circulating tumor cells and clinicopathological characteristics in well-differentiated nonfunctional pancreatic neuroendocrine tumors performed on CellSearch platform

被引:0
作者
Lv, Yang [1 ]
Xin, Bao-Bao [1 ]
Zhang, Lei [1 ]
Li, Jian-Ang [1 ]
Zhou, Jia-Ye [2 ]
Lou, Wen-Hui [1 ]
Jin, Da-Yong [1 ]
Xu, Xue-Feng [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Pancreat Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Clin Lab, Shanghai, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2017年 / 10卷 / 01期
关键词
Circulating tumor cells; pancreatic neuroendocrine tumors; clinical correlation; PERIPHERAL-BLOOD; STEM-CELL; CANCER; BIOMARKERS; MANAGEMENT; PROGNOSIS; DIAGNOSIS; HINDGUT; MARKERS; MIDGUT;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: to investigate the feasibility of the circulating tumor cells applied in well-differentiated nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) and present the pilot study of its clinical value using CellSearch platform. Method: From September 2014 to March 2016, 15 consecutive patients (7 males) who were pathologically diagnosed as well-differentiated NF-pNETs were enrolled in this study. 7.5 ml blood from the peripheral vein were drawn, detected and analyzed through the CellSearch system. The clinical characteristics, tumor grade, CTCs counts of each patient were recorded and statistically compared. Results: Of the 15 enrolled patients, 46.67% were males. All of the patients were NF-pNETs (26.67% G1, 73.33% G2) and 6 of them had liver metastases (LM). The median size of the primary lesion was 2.14 cm, and the median ki-67 index was 6.27%. CTC were detected in 53.33% of patients, the mean count was 2.2 CTCs (median 1). For all the recruited patients, compared with the control group, patients with lymph metastases (P=0.003), tumor size larger than 2 cm (P=0.020) and elevated CgA level (P=0.001) preoperatively were likely to have higher capture rate of tumor cells. Conclusion: CTCs detection from the peripheral blood is practical in well-differentiated NF-pNETs, which has the potential to suggest the prognosis. Further detection and exploration need to be continued.
引用
收藏
页码:680 / 687
页数:8
相关论文
共 30 条
[1]   Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients [J].
Aktas, Bahriye ;
Tewes, Mitra ;
Fehm, Tanja ;
Hauch, Siegfried ;
Kimmig, Rainer ;
Kasimir-Bauer, Sabine .
BREAST CANCER RESEARCH, 2009, 11 (04)
[2]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[3]   Challenges in circulating tumor cell detection by the CellSearch system [J].
Andree, Kiki C. ;
van Dalum, Guus ;
Terstappen, Leon W. M. M. .
MOLECULAR ONCOLOGY, 2016, 10 (03) :395-407
[4]   Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells [J].
Bourcy, Morgane ;
Suarez-Carmona, Meggy ;
Lambert, Justine ;
Francart, Marie-Emilie ;
Schroeder, Helene ;
Delierneux, Celine ;
Skrypek, Nicolas ;
Thompson, Erik W. ;
Jerusalem, Guy ;
Berx, Geert ;
Thiry, Marc ;
Blacher, Silvia ;
Hollier, Brett G. ;
Noel, Agnes ;
Oury, Cecile ;
Polette, Myriam ;
Gilles, Christine .
CANCER RESEARCH, 2016, 76 (14) :4270-4282
[5]   Circulating tumor cells in the diagnosis and management of pancreatic cancer [J].
Cen, Putao ;
Ni, Xiaoling ;
Yang, Jingxuan ;
Graham, David Y. ;
Li, Min .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2012, 1826 (02) :350-356
[6]  
Coumans F, 2015, METHODS MOL BIOL, V1347, P263, DOI 10.1007/978-1-4939-2990-0_18
[7]   Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer [J].
Earl, Julie ;
Garcia-Nieto, Sandra ;
Carlos Martinez-Avila, Jose ;
Montans, Jose ;
Sanjuanbenito, Alfonso ;
Rodriguez-Garrote, Mercedes ;
Lisa, Eduardo ;
Mendia, Elena ;
Lobo, Eduardo ;
Malats, Nria ;
Carrato, Alfredo ;
Guillen-Ponce, Carmen .
BMC CANCER, 2015, 15
[8]   Circulating tumor cell technologies [J].
Ferreira, Meghaan M. ;
Romani, Vishnu C. ;
Jeffrey, Stefanie S. .
MOLECULAR ONCOLOGY, 2016, 10 (03) :374-394
[9]   Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples [J].
Gogoi, Priya ;
Sepehri, Saedeh ;
Zhou, Yi ;
Gorin, Michael A. ;
Paolillo, Carmela ;
Capoluongo, Ettore ;
Gleason, Kyle ;
Payne, Austin ;
Boniface, Brian ;
Cristofanilli, Massimo ;
Morgan, Todd M. ;
Fortina, Paolo ;
Pienta, Kenneth J. ;
Handique, Kalyan ;
Wang, Yixin .
PLOS ONE, 2016, 11 (01)
[10]   Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls [J].
Gut, Pawel ;
Czarnywojtek, Agata ;
Fischbach, Jakub ;
Baczyk, Maciej ;
Ziemnicka, Katarzyna ;
Wrotkowska, Elzbieta ;
Gryczynska, Maria ;
Ruchala, Marek .
ARCHIVES OF MEDICAL SCIENCE, 2016, 12 (01) :1-9